Adam Keeney named head of corporate development at Biogen

5 April 2023

US biotech major Biogen (Nasdaq: BIIB) has appointed Adam Keeney as executive vice president, head of corporate development effective April 17, 2023, adding a new face to its business development team.

Dr Keeney will be a member of Biogen’s executive committee reporting to Christopher Viehbacher, president and chief executive of the company, which has been under pressure since the controversial approval and dismal roll-out of the Alzheimer’s drug Aduhelm (aducanumab).

“We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable experience in biopharmaceutical strategy and business development with a solid track record of value-creating deals throughout his career,” said Mr Viehbacher. “As we are working to put Biogen on a sustainable growth trajectory, Adam will focus on advancing the company’s strategy and pursuing external collaborations and other growth opportunities,” he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK